Association of inhibitors with each TNFA haplotype identified
Haplotype . | Total no. of patients . | Inhibitor positive, % . | High-responding inhibitors, % . |
|---|---|---|---|
| Hap 1-1 | 48 | 42.7 | 25.0 |
| Hap 2-2 | 18 | 77.8 | 77.8 |
| Hap 1-2 | 43 | 41.9 | 30.2 |
| Hap 1-3 | 14 | 28.6 | 21.4 |
| Hap 2-3 | 12 | 58.3 | 50.0 |
| Hap 1-4 | 8 | 37.5 | 12.5 |
| Hap 2-4 | 7 | 57.1 | 57.1 |
| Hap 1-5 | 4 | 25 | 0 |
| Hap 2-5 | 2 | 50 | 50 |
| Hap 2-6 | 2 | 50 | 0 |
| Hap 2-7 | 2 | 50 | 50 |
| Hap 3-4 | 2 | 100 | 100 |
Haplotype . | Total no. of patients . | Inhibitor positive, % . | High-responding inhibitors, % . |
|---|---|---|---|
| Hap 1-1 | 48 | 42.7 | 25.0 |
| Hap 2-2 | 18 | 77.8 | 77.8 |
| Hap 1-2 | 43 | 41.9 | 30.2 |
| Hap 1-3 | 14 | 28.6 | 21.4 |
| Hap 2-3 | 12 | 58.3 | 50.0 |
| Hap 1-4 | 8 | 37.5 | 12.5 |
| Hap 2-4 | 7 | 57.1 | 57.1 |
| Hap 1-5 | 4 | 25 | 0 |
| Hap 2-5 | 2 | 50 | 50 |
| Hap 2-6 | 2 | 50 | 0 |
| Hap 2-7 | 2 | 50 | 50 |
| Hap 3-4 | 2 | 100 | 100 |